Clovis Oncology, Inc., a biopharmaceutical company focused on commercializing anti-cancer agents, filed on Thursday with the SEC to raise up to $150 million in an initial public offering. The Boulder, CO-based company, which was founded in 2009, plans to list on the NASDAQ under the symbol CLVS. J.P. Morgan and Credit Suisse are the lead underwriters on the deal. No pricing terms were disclosed.
